French pharmaceutical giant Sanofi announced on Friday that its full-year 2022 sales increased by 7.0 per cent year-on-year to around 43 billion euros (47 billion US dollars).
Sales were up 12.2 per cent in the United States, 6.2 per cent in China and 2.4 per cent in Europe, the company said in a press release.
The increase in sales in China was mainly due to the inclusion of several Sanofi drugs in the National Reimbursement Drug List (NRDL), reports Xinhua.
The group's net profit rose by 8.0 per cent to 6.7 billion euros last year.
In 2022, net sales of pharmaceuticals increased by 6.9 per cent, mainly driven by the Specialty Care and General Medicines portfolios. Vaccine sales were up 6.3 per cent thanks to the progressive recovery of travel and booster vaccines.
The group also saw its consumer healthcare sales increase by 8.6 per cent in 2022.
Sanofi's COVID-19 vaccine, VidPrevtyn Beta, was approved by the European Commission as a booster for the prevention of COVID-19 in adults who have previously received an mRNA (messenger ribonucleic acid) or adenoviral COVID-19 vaccine.